- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02617017
Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson' Disease (BUSPARK)
Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson' Disease. Multicenter, International, Placebo-controlled, Randomised, Double Blind Trial
Parkinson's disease (PD) is one of the most common neurodegenerative diseases, with a higher prevalence in the elderly. Levodopa induced dyskinesias (LID) are a major motor complications that impair quality of life for patients with PD. The mechanisms of these dyskinesias remain unclear, but several hypotheses have been put forward: non continuous, pulsatile stimulation of dopaminergic receptors, or alterations of other neurotransmitters within the motor striatum such as glutamate and serotonin.
Few strategies are now available to treat severe LID:
- Medications: reduction of dopaminergic treatment, addition of amantadine,
- Functional neurosurgery. The purpose of this study is to investigate the efficacy of buspirone in PD patients suffering from dyskinesias. The role of serotonin in the occurrence of LID was recently demonstrated in transplant PD patients and a test double-blind, single dose was achieved. Following administration of 10 mg oral buspirone, a 5HT1A agonist, LID were clearly improved. A antidyskinetic effect of buspirone had already been reported in 1991 and 1994, but identification of buspirone as a serotonin receptor agonist has been reported more recently.
This trial is aimed at (1) validate the serotoninergic hypothesis of hyperkinetic levodopa induced dyskinesias (LID) in Pakinson's disease patients, (2) evaluate, in a phase 3 trial, the motor efficacy of buspirone to improve LID vs placebo, (3) look at a possible dose/effect relationship and (4) check the hypothesis of a better therapeutic ratio using the association of buspirone and amantadine instead than a single drug.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Florence Couppey, CRA
- Phone Number: +33 (0)1 49 81 37 52
- Email: florence.couppey@aphp.fr
Study Contact Backup
- Name: Gilles Fénelon, MD
- Phone Number: +33 (0)1 49 81 23 02
- Email: gilles.fenelon@aphp.fr
Study Locations
-
-
-
Creteil, France, 94010
- Henri Mondor Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria
- The subject is an out-patient between 35 year and 80 years of age
- Diagnosis of idiopathic Parkinson's disease according to the UK Parkinson's Disease Society Brain Bank Clinical Diagnosis Criteria
- Dyskinesias are present more than 25% of the waking day according to item 4-1 of MDS-UPDRS
- Dyskinesias are at least moderately disabling item 4-2 of MDS-UPDRS replaced by Dyskinesias are at least slightly disabling item 4-2 of MDS-UPDRS (amendment n°2)
- The subject is able to identify dyskinesia, ON and OFF, and apply to his/her own state
- Stable dose of anti-Parkinsonian drugs for at least 4 weeks up to the screening
- The subject is considered as being optimally treated at the time of inclusion
- Written and signed informed consent to participate in the study
- Maximal Hoehn and Yahr staging : III in "ON" phases, IV in "OFF"
- Active affiliation to social security
- Menopausal or under contraception for woman
Exclusion Criteria
- Female subjects : pregnant or lactating
- Atypical parkinsonian syndrome
- Weight less than 40 Kgs
- Mini-Mental State Examination (MMSE) less than 24
- The subject is participating in another clinical study within the past 12 weeks
- Planned participation in another therapeutic clinical study
- Previous treatment with buspirone, less than 6 months before Week 0
- Known allergy to buspirone
- Known lactose intolerance
- Clinically significant illness that might interfere with the study
- Dementia or other psychiatric illness
- Drug or alcohol abuse replaced by Substance use disorder (alcohol i.e. > 3 drinks per day for men and > 2 drinks per day for women,drug, medicinal product) (amendment n°1)
- Legal incapacity or limited legal capacity
- Deep brain stimulation performed less than 12 months before protocol initiation, or unstable parameters of stimulation 4 weeks before week 0
- Severe renal and / or hepatic impairment
- History of seizures or epilepsy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Capsules of placebo will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)
|
Experimental: Buspirone
|
Capsules of buspirone will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Between-group comparison of changes in UDysRS scores
Time Frame: Between baseline and week 12
|
Between baseline and week 12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Comparison, in both groups of patients of side effects (tolerance)
Time Frame: At week Week-2, Week0, Week2, Week4, Week12, Week13
|
At week Week-2, Week0, Week2, Week4, Week12, Week13
|
Maximum dose accepted by patients (tolerance)
Time Frame: At week Week-2, Week0, Week2, Week4, Week12, Week13
|
At week Week-2, Week0, Week2, Week4, Week12, Week13
|
Comparison, in both groups of patients of Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part 3-4 (efficacy)
Time Frame: At week 0,Week2, Week4, Week12, Week13
|
At week 0,Week2, Week4, Week12, Week13
|
Comparison, in both groups of patients of MDS-UPDRS part 1-2 (quality of life)
Time Frame: At week Week-2, Week0, Week2, Week4, Week12, Week13
|
At week Week-2, Week0, Week2, Week4, Week12, Week13
|
Comparison, in both groups of patients of PDQ-39 (quality of life)
Time Frame: At week 0 and week 12
|
At week 0 and week 12
|
Collaborators and Investigators
Investigators
- Principal Investigator: Philippe Rémy, PhD, Assistance Publique - Hôpitaux de Paris
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Parkinson Disease
- Dyskinesias
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Serotonin Receptor Agonists
- Anti-Anxiety Agents
- Buspirone
Other Study ID Numbers
- P130909
- 2015-002332-41 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
Bial - Portela C S.A.Completed
-
Abbott Medical DevicesBaylor College of Medicine; University of HoustonCompleted
-
Mayo ClinicCompleted
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Beijing Pins Medical Co., LtdUnknownIdiopathic Parkinson PatientsChina
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
Clinical Trials on Buspirone
-
Johns Hopkins Bloomberg School of Public HealthJohns Hopkins University; Massachusetts General Hospital; National Institute... and other collaboratorsCompleted
-
Massachusetts General HospitalBrainCells Inc.CompletedMajor Depressive DisorderUnited States
-
Beijing Union Pharmaceutical Factory LtdR&G Pharma Studies Co.,Ltd.RecruitingGeneralized Anxiety DisorderChina
-
Spaulding Rehabilitation HospitalRecruitingSpinal Cord InjuriesUnited States
-
Par Pharmaceutical, Inc.Phoenix International Life Sciences, Inc.CompletedTo Determine Bioequivalence Under Fed ConditionsCanada
-
Par Pharmaceutical, Inc.Phoenix International Life Sciences, Inc.CompletedTo Determine Bioequivalence Under Fasting ConditionsCanada
-
Laikο General Hospital, AthensCompleted
-
University of OxfordCompleted
-
Nordic Life Science Pipeline Inc.United States Department of DefenseCompleted
-
Northwestern UniversityNational Alliance for Research on Schizophrenia and DepressionCompletedSchizophrenia | Schizoaffective DisorderUnited States